United States — the fast-moving centre
The United States is where the regulatory stakes are highest and where change is happening fastest. Ibogaine remains a Schedule I controlled substance under federal law — meaning it is officially classified as having no accepted medical use and a high potential for abuse. But a series of developments in 2025 and 2026 have begun to challenge that classification in practice, if not yet in law.
United States — Federal status
Schedule I · DEA Controlled Substances Act · Under active review 2026
Ibogaine is classified as a Schedule I substance under the Controlled Substances Act, enforced by the Drug Enforcement Administration. This classification makes it federally illegal to possess, distribute, or administer — and has historically made clinical research extremely difficult to conduct within US borders.
A 2026 executive order directed federal agencies including the FDA to accelerate the review of ibogaine and other psychedelics, explore patient access pathways under Right to Try provisions, and consider rescheduling if clinical trial evidence and FDA approval criteria are met. This represents the most significant shift in federal posture toward ibogaine since it was placed in Schedule I in 1970. Ibogaine nonetheless remains Schedule I: the order speeds up review, it does not change the law.
What "Right to Try" means for ibogaine
The 2026 executive order references Right to Try — a federal law originally designed for terminal patients to access unapproved treatments. Its application to ibogaine would potentially allow access to patients with serious conditions before formal FDA approval, under specific conditions. The exact scope and implementation of this pathway for ibogaine is still being determined by federal agencies as of this writing.
Country by country
Americas
United States
Schedule IFederally illegal under the Controlled Substances Act. Enforcement by the DEA. Underground clinics known to exist despite active surveillance. 2026 executive order initiates review process — status may change if FDA approval criteria are met.
Canada
Prescription onlyHealth Canada added ibogaine to the Prescription Drug List in 2017, after receiving reports of serious and fatal adverse reactions. It is not a controlled substance, so possession is not criminalised, but it may only be sold on prescription and it is not authorised for any medical use. The open treatment clinics that existed before 2017 have largely closed.
Source: Health Canada, Notice on Prescription Drug List additions, May 2017.
Mexico
Grey areaIbogaine is not scheduled in Mexico, and treatment clinics — many of them serving US patients — operate openly, particularly in Baja California. The regulatory framework is inconsistent, and standards vary widely between providers.
Costa Rica
Grey areaTreatment centres operate in Costa Rica. Ibogaine is not explicitly scheduled, creating a permissive environment for clinics serving international clients.
Bahamas
Grey areaTreatment clinics operate in the Bahamas, catering largely to US patients. Ibogaine is not scheduled, and the country's proximity to the US has made it a significant treatment destination.
Europe
Netherlands
Grey areaIbogaine is not scheduled as a controlled substance in the Netherlands. Treatment providers operate, and the Netherlands has historically been a centre for ibogaine research and practice in Europe. Howard Lotsof conducted early clinical work here.
United Kingdom
ControlledIbogaine falls under the Psychoactive Substances Act 2016, which prohibits the supply of psychoactive substances not otherwise covered by the Misuse of Drugs Act. Possession for personal use is not directly criminalised, but supply and administration are.
France
IllegalLambarène, the low-dose ibogaine tonic, was withdrawn from the French market in the late 1960s. Iboga, ibogaine and their derivatives were formally added to France's list of narcotics in March 2007, making possession and distribution illegal.
Historically notable as the country where ibogaine was first commercially sold.
Germany
Grey areaIbogaine is not listed in the German narcotics law (Betäubungsmittelgesetz), so possession is not a criminal offence. It is also not an approved medicine: doctors cannot treat patients with it outside research, and offering it as a treatment sits in a legal grey area under medicines law.
Belgium
ControlledControlled under Belgian drug law. Notable as the country where Howard Lotsof contracted to produce ibogaine for early clinical trials in the 1980s.
Africa & Oceania
Gabon
LegalIboga and ibogaine are legal and culturally protected in Gabon, the homeland of the Bwiti tradition. The plant is considered a national heritage. Export of Tabernanthe iboga root bark is regulated to protect wild populations.
South Africa
Prescription onlyIn 2016 South Africa's medicines regulator resolved to list ibogaine as a Schedule 6 substance under the Medicines and Related Substances Act, which makes it prescription-only. Treatment clinics continue to operate, and the country has an active ibogaine treatment community, including a notable tradition of treating addiction to nyaope (a local drug mixture).
New Zealand
Prescription onlyIbogaine is classified as a prescription medicine in New Zealand — one of the few countries where it has a defined legal status short of full prohibition. Licensed providers can administer it under medical supervision. New Zealand has been a site of noribogaine clinical trials.
Australia
Prescription onlySince 2010 ibogaine has been listed in Schedule 4 (prescription-only medicines) of Australia's Poisons Standard. It is not a controlled drug, so possession is not criminalised, but it is not an approved medicine and may not be supplied without a prescription. Australia's progressive approach to psychedelic therapy (it became the first country to formally approve MDMA and psilocybin therapy in 2023) may create a pathway for ibogaine in future.
Where treatment clinics operate
Treatment clinics offering ibogaine have established themselves in countries where the legal environment permits, catering significantly to patients from the United States, UK, and other countries where ibogaine is prohibited. Standards vary considerably — from highly medicalised, well-supervised settings to operations with minimal safety infrastructure.
Known treatment clinic locations — as of 2026
Mexico
Largest concentration of clinics. Primarily in Baja California near the US border. Standards vary widely.
Netherlands
Historically significant. Several established providers with longer track records.
South Africa
Active treatment community. Significant tradition treating local opiate addiction.
Bahamas
Proximity to US makes it a popular destination. Several established operations.
Costa Rica
Growing number of providers. Increasingly popular with North American patients.
New Zealand
Prescription framework allows licensed clinical provision. More regulated than most.
Portugal
Permissive drug environment. Some providers operating, growing interest.
Gabon
Traditional Bwiti ceremony. A small number of Western-facing retreat providers.
A note on clinic quality
The existence of a treatment clinic in a country where ibogaine is legal or unscheduled does not imply that the clinic meets adequate safety standards. The Global Ibogaine Therapy Alliance published clinical guidelines in 2015, but compliance is voluntary and unverifiable from the outside.
If you are considering treatment, our For Those Considering Treatment page provides specific guidance on evaluating any provider, including the questions you should ask before proceeding.
International scheduling
Ibogaine is not scheduled under international drug control conventions — including the UN Single Convention on Narcotic Drugs (1961) or the Convention on Psychotropic Substances (1971). This means that international law does not require countries to prohibit it, and national status varies according to each country's own scheduling decisions.
In the late 1960s, the World Health Assembly classified ibogaine as a substance likely to cause dependency or endanger human health — a classification that influenced subsequent national scheduling decisions. The International Olympic Committee banned ibogaine as a potential doping agent during the same period.
The absence of international scheduling is significant: it means that the legal reform process, should clinical trials generate the evidence needed, would need to happen country by country — there is no single international body that would need to act first.